Corey Davis
Stock Analyst at HC Wainwright & Co.
(2.49)
# 2,301
Out of 4,862 analysts
17
Total ratings
64.29%
Success rate
9.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corey Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Reiterates: Neutral | $32 → $26 | $8.59 | +202.68% | 5 | May 12, 2020 | |
| SCYX SCYNEXIS | Assumes: Buy | $50 | $0.81 | +6,105.01% | 3 | May 7, 2018 | |
| VTVT vTv Therapeutics | Downgrades: Neutral | $560 → $40 | $15.54 | +157.40% | 2 | Apr 10, 2018 | |
| LPCN Lipocine | Initiates: Buy | $170 | $3.12 | +5,357.11% | 1 | Mar 29, 2018 | |
| VNDA Vanda Pharmaceuticals | Initiates: Buy | $20 | $4.51 | +343.46% | 2 | Jan 19, 2018 | |
| PCRX Pacira BioSciences | Initiates: Buy | $50 | $24.24 | +106.27% | 3 | Jan 19, 2018 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Neutral | $144 | $108.50 | +32.72% | 1 | Aug 25, 2017 |
Nektar Therapeutics
May 12, 2020
Reiterates: Neutral
Price Target: $32 → $26
Current: $8.59
Upside: +202.68%
SCYNEXIS
May 7, 2018
Assumes: Buy
Price Target: $50
Current: $0.81
Upside: +6,105.01%
vTv Therapeutics
Apr 10, 2018
Downgrades: Neutral
Price Target: $560 → $40
Current: $15.54
Upside: +157.40%
Lipocine
Mar 29, 2018
Initiates: Buy
Price Target: $170
Current: $3.12
Upside: +5,357.11%
Vanda Pharmaceuticals
Jan 19, 2018
Initiates: Buy
Price Target: $20
Current: $4.51
Upside: +343.46%
Pacira BioSciences
Jan 19, 2018
Initiates: Buy
Price Target: $50
Current: $24.24
Upside: +106.27%
Jazz Pharmaceuticals
Aug 25, 2017
Initiates: Neutral
Price Target: $144
Current: $108.50
Upside: +32.72%